Dare Bioscience, Inc. quarterly report, Q3 FY2021

Dare Bioscience, Inc. — Q3 2021 Form 10-Q

Reporting period: Quarter and nine months ended September 30, 2021. Dare is a clinical-stage women’s health biopharmaceutical company with no approved or commercialized products and no revenue to date.

Financial performance and position

MetricQ3 2021Q3 2020Nine months 2021Nine months 2020
Revenue$0$0$0$0
Research and development expense$10.43 million$6.20 million$23.50 million$14.13 million
General and administrative expense$2.21 million$1.35 million$5.95 million$4.77 million
Net loss$12.67 million$7.58 million$29.15 million$18.96 million
Loss per share, basic and diluted$0.18$0.24$0.45$0.69
Operating cash usedNot separately statedNot separately stated$18.85 million$16.04 million

There are no meaningful revenue-based margins to report. At September 30, cash and cash equivalents were $45.57 million, working capital was approximately $32.3 million, and accumulated deficit was $100.6 million. Total liabilities were $16.92 million, including $11.16 million of deferred grant funding; the company reported no note payable at quarter-end. Total assets were $48.81 million.

Financing activities provided $59.84 million in the first nine months, primarily from common-stock offerings. The company raised approximately $52.7 million net through ATM offerings and $6.8 million net through its equity line; it also received $255,000 from warrant exercises. Shares outstanding rose from 41.6 million at December 31, 2020 to 76.6 million at September 30, 2021.

Material changes and operating developments

  • Q3 net loss increased by $5.08 million year over year; nine-month net loss increased by $10.19 million. Higher clinical and development spending was the principal driver, partly offset by completion of the DARE-BV1 Phase 3 trial in December 2020.
  • Nine-month R&D expense rose $9.37 million, including increased spending on the Sildenafil Cream Phase 2b trial and Ovaprene manufacturing and regulatory work, as well as earlier-stage programs.
  • Nine-month cash used in operations increased to $18.85 million from $16.04 million. The 2021 period included a $9.59 million increase in deferred grant funding, which supported operating cash flow.
  • The $367,285 PPP loan and accrued interest were forgiven in January 2021, producing a $369,887 gain on extinguishment.
  • The company issued approximately 700,000 shares in September to satisfy $1.25 million of MBI-related milestone consideration, with $75,000 paid in cash.

Outlook, risks and notable items

  • Going concern and capital: Management stated that the company’s current operating plan did not provide sufficient cash for working-capital needs and other liquidity requirements over at least the next 12 months from the financial statements’ issuance date. The filing identifies substantial doubt about the company’s ability to continue as a going concern and says additional capital is needed. Future financing could dilute shareholders; unavailable or unfavorable funding could force development reductions or cessation of operations.
  • Spending outlook: Management expected 2021 R&D expense to be approximately double 2020 levels and expected R&D and operating expenses to rise further in 2022. It estimated 2021 G&A expense would increase approximately 20% versus 2020, potentially more depending on DARE-BV1 commercialization plans. The Sildenafil Cream Phase 2b trial was estimated to cost approximately $15–$20 million in aggregate, with less than half expected to be fiscal 2021 expense.
  • DARE-BV1: The FDA accepted the NDA and granted Priority Review in August 2021, with a target action date of December 7, 2021. If approved, the company expected a U.S. launch in the first half of 2022. Commercialization strategy was not finalized, and the company lacked a commercial partner or internal sales infrastructure. FDA review, a possible complete response letter, launch timing, competition from generics and commercialization funding are material uncertainties.
  • Ovaprene: A July 2021 agreement with NICHD provides for a pivotal Phase 3 study; the company anticipated starting it in 2022. Dare is responsible for $5.5 million of study costs. It had paid $250,000 by September 30 and subsequently paid $1.25 million in November; a further $3.5 million payment was due in Q1 2022 and $500,000 in Q2 2023. Bayer’s U.S. license becomes effective only if Bayer elects to pay an additional $20 million; Bayer may terminate on 90 days’ notice.
  • Other development and grants: Enrollment in the Sildenafil Cream Phase 2b trial was slower than expected, with no reliable interim-analysis or topline-data date stated. The company reported positive Phase 1 topline results for DARE-HRT1 and initiation of a Phase 1/2 study for DARE-VVA1, with DARE-VVA1 topline results anticipated in 2022. A Gates Foundation award provides up to $48.95 million for DARE-LARC1 development, but only $11.45 million had been received by September 30; further payments depend on milestones and compliance.
  • COVID-19 and third parties: The company said the pandemic had not materially adversely affected operations to date, but slower trial enrollment and supply-chain and staffing constraints had delayed or could delay development activities, increase costs and impair access to capital. The company depends on CROs, manufacturers and other third parties; Ovaprene’s pivotal study is particularly dependent on NICHD and its contractors.
  • Subsequent financing: On October 13, 2021, Dare entered a new ATM agreement for up to $50 million in common stock, with a 3% sales commission. The filing does not state proceeds from this new agreement through the filing date.

Most important facts for investors to verify

  • Whether the FDA acted on the DARE-BV1 NDA by its December 7, 2021 target date, and the resulting approval, labeling and launch requirements.
  • Cash runway and financing needs against the company’s stated going-concern doubt, including the effect of subsequent ATM sales and expected development spending.
  • Progress and enrollment timelines for the Sildenafil Cream trial and planned Ovaprene Phase 3 study, including NICHD payment obligations and any delays.
  • Terms and timing of DARE-BV1 commercialization arrangements and the associated funding requirements, as well as Bayer’s decision on the Ovaprene license option.
  • Milestone conditions for future DARE-LARC1 grant payments and whether the funded development program advances as planned.
  • Further share issuance and dilution: common shares increased substantially during 2021, and the October ATM permits additional issuance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.